Arcturus Therapeutics is losing its second executive in as many weeks—Pad Chivukula, the RNA biotech’s chief scientific officer and chief operating officer, is stepping down.
Chivukula will take an advisory role with Arcturus, which headlined its announcement with the appointment of Christine Esau, previously its senior director of translational research, to the top R&D post at the company.
“It has been a privilege to be a part of the Arcturus team, and I am proud of our extraordinary innovations and accomplishments in advancing our diverse pipeline of RNA therapeutics and the many partnerships we have garnered thus far, Chivukula said in the statement. “I look forward to following the Company’s ongoing success as Arcturus continues to progress its preclinical programs.”
The news comes shortly after Arcturus’ board voted to oust then-President and CEO Joseph Payne, who was replaced in the interim with Mark Herbert, the company’s VP of business development and alliance management.
Payne didn’t go down without a fight. He had his attorneys pen a letter to Arcturus, claiming that the board of directors excluded both him and Chivukula from “board discussions and votes,” which is how he, as CEO and a board member, missed the memo that he was getting fired.
The letter laid the blame on a group of four directors—Stuart Collinson, executive chairman of the board, Craig Willett, Daniel Geffken and Intercept CMO David Shapiro—who made the decision in violation of Israeli Companies Law and then “had our client physically removed from the building.”
It also demanded Payne be reinstated in his old job, but Arcturus countered, saying he was terminated because his conduct was “contrary to the best interests of the Company and its shareholders” and that Payne had “demonstrated that he is unable to put the needs of the company and its shareholders ahead of his own self-interest.”
Arcturus backed its way onto the Nasdaq in September, through a reverse merger with Israel-based Alcobra, which, the letter alleged, is the root of “the poor corporate governance demonstrated in recent months,” that led to his ouster.
By Amirah Al Idrus
Source: Fierce Biotech
Giovanni Caforio, the former CEO of Bristol Myers Squibb, is set to become the next board chairman of Novartis, which on Tuesday proposed the pharmaceutical industry veteran as its pick to replace Joerg Reinhardt in the role next year. Reinhardt has served as Novartis’ chair since 2013 and plans to retire when his 12-year term ends in 2025.
GE HealthCare has raised the curtain on two ultrasound systems equipped with artificial intelligence programs designed to assist in diagnosing conditions in women’s health, including obstetric exams. The Voluson Signature 20 and 18 imaging systems include AI tools capable of automatically identifying and annotating measurements of fetal anatomy.
Scientists from the University of Edinburgh’s School of Chemistry have revealed a new sustainable method of manufacturing complex molecules that could reduce waste produced during drug production. The method published in Nature Chemistry could help to prevent severe side effects caused by drugs that can exist as enantiomers.
